We are live on ! Find out more
PODD icon

Insulet

186 hedge funds and large institutions have $2.91B invested in Insulet in 2014 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 68 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 16

80% more funds holding in top 10

Funds holding in top 10: 59 (+4)

70% more call options, than puts

Call options by funds: $6.21M | Put options by funds: $3.65M

27% more capital invested

Capital invested by funds: $2.29B → $2.91B (+$621M)

14% more funds holding

Funds holding: 163186 (+23)

18% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 68

Holders
186
Holders Change
+23
Holders Change %
+14.11%
% of All Funds
5.35%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.26%
New
43
Increased
56
Reduced
68
Closed
16
Calls
$6.21M
Puts
$3.65M
Net Calls
+$2.56M
Net Calls Change
+$11.4M

PODD Hedge Fund Activity: Q1 2014 in Review

186 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Insulet (PODD) for Q1 2014, worth a combined $2.91B — up 27% from $2.29B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new PODD positions and 16 closed out — a net gain of 27 holders — while 56 added to existing stakes and 68 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $39.4M. The largest seller was OrbiMed, cutting an estimated $42.2M.

  • 186 institutional investors held Insulet (PODD) as of Q1 2014, up from 163 in Q4 2013.
  • Funds reported $2.91B of Insulet stock for Q1 2014, up 27% quarter-over-quarter.
  • 43 funds opened new Insulet positions in Q1 2014 and 16 closed out, a net change of +27 holders.
  • The largest Insulet buyer in Q1 2014 was Wellington Management Group, an estimated $39.4M added.
  • The largest Insulet seller in Q1 2014 was OrbiMed, an estimated $42.2M sold.

Based on aggregated 13F filings for Q1 2014.